Cisplatin every 3 weeks versus weekly with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck

JM Bauml, R Vinnakota, YH Anna Park… - JNCI: Journal of the …, 2019 - academic.oup.com
Background Concurrent chemoradiotherapy is an established component of the
nonoperative management of locally advanced head and neck squamous cell carcinoma …

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell …

DJ Adelstein, Y Li, GL Adams, H Wagner Jr… - Journal of clinical …, 2003 - ascopubs.org
Purpose: The Head and Neck Intergroup conducted a phase III randomized trial to test the
benefit of adding chemotherapy to radiation in patients with unresectable squamous cell …

Concomitant chemoradiation in locally advanced head and neck squamous cell carcinoma: A literature-based meta-analysis on the platinum concomitant …

MG Ghi, A Paccagnella, I Floriani… - Journal of Clinical …, 2011 - ascopubs.org
5534 Background: Concomitant platinum-based chemoradiation (CRT) is the standard
treatment for locally advanced squamous cell carcinoma. As no consensus regarding the …

High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and …

G de Castro, IML Snitcovsky, EMMS Gebrim… - European archives of …, 2007 - Springer
Unresectable head and neck squamous cell carcinoma (HNSCC), non-metastatic,
comprises a heterogeneous group of patients (pts), formed of stage III and IV pts. Since the …

Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck

B Jeremic, B Milicic, A Dagovic, Z Vaskovic… - Journal of clinical …, 2004 - ascopubs.org
Purpose To retrospectively investigate the difference between conventionally fractionated
(CF) and hyperfractionated (Hfx) radiation therapy (RT), with and without either daily …

The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic …

K Uygun, A Bilici, H Karagol, M Caloglu, I Cicin… - Cancer chemotherapy …, 2009 - Springer
Purpose Several studies have shown that the concurrent administration of chemotherapy
(CHT) and radiotherapy (RT) is superior to RT alone in patients with inoperable non …

Results of EORTC phase III trial 22931 comparing, postoperatively, radiotherapy (RT) to concurrent chemo-radiotherapy (RT-CT) with high dose cisplatin in locally …

J Bernier, M Van Glabbeke, C Domenge… - European Journal of …, 2001 - elibrary.ru
RESULTS OF EORTC PHASE III TRIAL 22931 COMPARING, POSTOPERATIVELY,
RADIOTHERAPY (RT) TO CONCURRENT CHEMO-RADIOTHERAPY (RT-CT) WITH HIGH …

A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome.

K Ang, Q Zhang, RH Wheeler, DI Rosenthal… - Journal of Clinical …, 2010 - ascopubs.org
5507 Background: Data of patients with stage III-IV HNC accrued in a phase III trial of
cisplatin (CDDP) plus an accelerated concomitant boost (AFX-C, 72 Gy/6 W) versus …

High‐dose or low‐dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer

CL Chang, KSP Yuan, SY Wu - Head & Neck, 2017 - Wiley Online Library
Background No randomized studies have compared low‐dose or high‐dose concurrent
chemoradiotherapy (CRT). Methods In this study, 7219 patients with stage III or IV head and …

Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer.

V Noronha, A Joshi, VM Patil, J Agarwal, SG Laskar… - 2017 - ascopubs.org
6007 Background: Chemoradiation (CRT) with cisplatin 100mg/m2 given 3-weekly is the
standard of care in locally advanced head and neck squamous cell cancer (HNSCC) …